Across TCGA pan-cancer cohorts, CLEC11A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CLEC11A data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CLEC11A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLEC11A expression acts as an unfavorable survival marker.
CESC are the cancer types where CLEC11A Mutation most reproducibly stratifies survival.